Advanced Cancer Pain Management Market is segmented By Drug Class (Monoclonal Antibody, Cannabinoid, Aminoindane), By Route of Administration (Intrave....
Market Size in USD
CAGR5.6%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 5.6% |
Market Concentration | High |
Major Players | Tetra Bio-Pharma, Medlab Clinical Ltd, GW Pharmaceuticals, Pharmascience Inc., PharmaCielo |
The Global Advanced Cancer Pain Management Market is estimated to be valued at USD 8.1 Bn in 2024 and is expected to reach USD 12.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.6% from 2024 to 2031. The rising prevalence of cancer across the world coupled with increasing demand for effective pain management drugs and therapies for advanced cancer patients are the key factors driving the growth of this market. Advanced pain management options have significantly improved the quality of life of cancer patients.
The Advanced Cancer Pain Management market is expected to grow steadily over the forecast period owing to rising incidences of cancer and increasing adoption of advanced pain therapies. The market is witnessing introduction of novel drug delivery methods and combination therapies that help provide better pain relief with lesser side effects. Moreover, increased awareness among patients, healthcare providers as well as government support are also expected to boost the demand for effective pain management in advanced cancer treatment.